T1Type1Cure
Video still from YouTube community video: Why Delaying Type 1 Diabetes Matters: Voices from the Research Community
YouTube community video (YouTube) / Source publication — credited and linked
Cure Research/June 26, 2026/2 min read

Why Delaying Type 1 Diabetes Matters: Voices from the Research Community

At a 2023 JDRF symposium, researchers, clinicians, and people living with Type 1 diabetes shared why intercepting and delaying the disease could transform millions of lives. Here's what that vision means in practice.

cureresearchclinical trial

Key takeaways

  • Delaying the onset of Type 1 diabetes could give millions of children years free from daily management demands like pumps, blood sugar monitoring, and dietary restrictions.
  • Research into interception and delay requires diverse perspectives—clinicians, scientists, and the Type 1 community working together produce richer, more meaningful science.
  • For people already living with Type 1, clinical advances offer hope for a future where the constant mental and physical burden of disease management becomes optional rather than essential.

A Child's Perspective on Living with Type 1

Evelyn, a JDRF advocate from South Australia, has lived with Type 1 diabetes since age six. For nine years, she has navigated the daily realities most children with Type 1 know well: insulin pumps, managing blood sugar highs and lows, and missing out on activities her peers take for granted. Like many young people with Type 1, Evelyn has no memory of life before diabetes management became part of her routine.

What Evelyn and her family see in clinical research is not just incremental improvement, but transformation. Intercepting and delaying the onset of Type 1 means future children could have years—or a lifetime—free from these constraints. They could eat without calculating insulin, play sports without worrying about blood sugar crashes, and simply be kids.

Why Research Needs Community Voices

The JDRF symposium that featured Evelyn's story brought together clinicians, researchers, and community members to shape a two-day program on intercepting and delaying Type 1 diabetes. This diversity of perspective—blending scientific expertise with lived experience—directly influences the quality and focus of research presentations.

When families like Evelyn's contribute to research planning, scientists better understand not just the medical dimensions of Type 1, but the human ones: the stress, the missed opportunities, the daily mental load. That insight shapes which questions researchers ask and how they measure success.

The Promise of Interception and Delay

Intercepting and delaying Type 1 diabetes is not a cure, but it represents a profound shift in what is possible. For millions of at-risk children worldwide, these approaches could mean postponing or preventing the disease from taking hold—buying time, reducing or eliminating years of intensive management, and restoring the freedom to grow up without the constant presence of diabetes.

For those already living with Type 1, like Evelyn, the research matters differently. It offers hope that future children—her siblings, cousins, classmates—might never know the life she knows. That vision drives the scientists, clinicians, and advocates working together to turn interception and delay from promise into reality.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.